Abiomed (ABMD) Posts Q4 GAAP EPS of $2.24
Get Alerts ABMD Hot Sheet
EPS Growth %: -100.0%
Financial Fact:
Costs and Expenses, Total: 88.45M
Today's EPS Names:
FSI, RELV, NEOM, More
Join SI Premium – FREE
Abiomed (NASDAQ: ABMD) reported Q4 EPS of $2.24, which may not compare with the analyst estimate of $0.14. Revenue for the quarter came in at $67.6 million versus the consensus estimate of $62.55 million.
Fiscal fourth quarter GAAP income from operations totaled $12.4 million, up 235% compared to $3.7 million in the prior year. GAAP net income included an income tax benefit of $86.5 million largely due to the release of the valuation allowance on most of Abiomed's deferred tax assets. The release of the valuation allowance is a onetime accounting adjustment with the offset recorded on the balance sheet as short and long term deferred tax assets based on the Company's estimates of sustainable profitability.
For earnings history and earnings-related data on Abiomed (ABMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2 reasons why Tesla stock fell on Thursday
- NaaS Technology Inc. (NAAS) Reports Q1 Loss of $0.29
- Pineapple Energy Inc. (PEGY) Misses Q4 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!